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B cells produce a diverse antibody repertoire by un-
dergoing gene rearrangements. Pathogen exposure
induces the clonal expansion of B cells expressing
antibodies that can bind the infectious agent. To
assess human B cell responses to trivalent seasonal
influenza and monovalent pandemic H1N1 vaccina-
tion, we sequenced gene rearrangements encoding
the immunoglobulin heavy chain, a major determi-
nant of epitope recognition. The magnitude of B
cell clonal expansions correlates with an individual’s
secreted antibody response to the vaccine, and the
expanded clones are enriched with those expressing
influenza-specific monoclonal antibodies. Addition-
ally, B cell responses to pandemic influenza H1N1
vaccination and infection in different people show a
prominent family of convergent antibody heavy chain
gene rearrangements specific to influenza antigens.
These results indicate that microbes can induce spe-
cific signatures of immunoglobulin gene rearrange-
ments and that pathogen exposure can potentially
be assessed from B cell repertoires.
INTRODUCTION
Human B cells generate a vast diversity of antibodies by rear-
ranging the genes encoding immunoglobulins V (variable), DCell(diversity), and J (joining) in their genomes (Tonegawa, 1983).
For decades, most monitoring of human antibody responses
to infections or vaccines has been performed by serological
measurements that can evaluate antibody specificities but
has provided only limited insight into the underlying changes
in clonal populations of B cells, or the gene rearrangements
responsible for the antibodies. More recently, single-cell sorting
and cloning of antibody genes, as well as optimized culture
systems and hybridoma generation, have given greater insight
into the specificity and breadth of reactivity of the antibodies
produced by influenza-specific B cells and molecular under-
standing of the genes encoding such antibodies (Li et al.,
2012; Wrammert et al., 2011; Wrammert et al., 2008; Yu
et al., 2008). High-throughput DNA sequencing methods now
permit detailed monitoring of B cell repertoires in humans
and are starting to be applied extensively to the study of vac-
cine responses (Boyd et al., 2009; DeKosky et al., 2013; Jiang
et al., 2013; Krause et al., 2011; Liao et al., 2011; Wu et al.,
2011).
It is largely unknown whether different people use similar anti-
body genes in their responses to common pathogen-associated
antigens.With a few exceptions, such as the antibody responses
to repetitive polysaccharide antigens (Ademokun et al., 2011;
Park et al., 1996; Scott et al., 1989; Silverman and Lucas,
1991), there has been little evidence of similarity between
different humans’ responses to most pathogens. Indeed, anti-
bodies would themselves be expected to exert a selection pres-
sure upon the pathogens they target and thus cause pathogens
to avoid expressing antigens that are recognized by human anti-
body genes.Host & Microbe 16, 105–114, July 9, 2014 ª2014 Elsevier Inc. 105
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response to influenza vaccination and used deep sequencing
to identify within a week of vaccination clonal expansion signa-
tures that correlate with the magnitude of the serological
response in vaccinated individuals. Comparison of expanded
clones to influenza-specific plasmablasts identified by single-
cell sorting from the same subjects demonstrated substantial
overlap between these populations. More surprisingly, we iden-
tified shared convergent antibody responses to the H1N1 2009
influenza strain among different people in response to both
vaccination and infection. These results represent an example
of a signature in immunoglobulin gene rearrangements specific
to the pathogen that elicited them and suggest that features of
an individual’s history of pathogen exposure can be identified
by sequence analysis.
RESULTS
Deep Sequencing of Rearranged IGH from the Trivalent
Inactivated Seasonal Influenza Vaccine Response
To take an overview of B cell responses induced by vaccination,
we carried out deep sequencing of immunoglobulin heavy chain
(IGH) from peripheral-blood B cells of 14 healthy young individ-
uals vaccinated with the 2007 or 2008 trivalent inactivated
seasonal influenza vaccine (TIV) (Moody et al., 2011). Seven indi-
viduals were ‘‘seroconverters,’’ who raised at least a 4-fold in-
crease in titer above baseline to two or more vaccine antigens,
as measured by ELISA against purified hemagglutinins (HAs).
The other seven individuals were ‘‘nonseroconverters,’’ who
failed to increase their vaccine-specific antibody to meet these
criteria (Table S1, available online) (Moody et al., 2011).
Twelve replicate IGH libraries were prepared from inde-
pendent genomic DNA template aliquots from cryopreserved
peripheral-blood mononuclear cells for each individual at each
of three time points: prevaccination, day 7 postvaccination,
and day 21 postvaccination (Figure 1A). On average, 35,436
IGH sequences were analyzed for each individual. Sequencing
depth was relatively evenly distributed across the time points;
there were an average of 11,661 IGH sequences prevaccination,
12,200 at day 7, and 11,564 at day 21.
B Cell Clonal Signatures from Deep Sequencing
Correspond to Serological Measures of Vaccine
Response
Clonally related B cell lineages were identified by the presence
of identical, or near identical, IGH in independent replicate
sequence libraries from genomic DNA for each time point. This
approach ensures that high expression of antibody gene
mRNA in individual cells, or amplification bias, is not misinter-
preted as evidence of clonal B cell populations. Most sero-
converters showed a response with one to three larger clones
and variable numbers of smaller clones, although subject
7024, who showed a predominance of smaller lineages, was
an exception. The median number of expanded clones for sero-
converters at day 7 was 69 (range 39–92), whereas the median
for nonseroconverters was 25 (range 8–85).
To compare the clonal signatures between samples, we used
a previously described clonality index (Wang et al., 2014). The
clonality index is a scale-independent normalized measure that106 Cell Host & Microbe 16, 105–114, July 9, 2014 ª2014 Elsevier Inreflects the probability that two independent sequences derive
from clonally related B cells (Figure 1B). Each of the seroconvert-
ers showed a prominent increase in clonality on day 7 in compar-
ison to prevaccination (Movie S1).Measured changes in clonality
from prevaccination to day 7 ranged from 3.38-fold to 247.57-
fold among seroconverters. Nonseroconverters showed a
mixture of modestly increased (four individuals) and modestly
decreased (three individuals) indices (Figure 1B).
The change in B cell clonality by day 7 was positively cor-
related with the fold change in antibody titer against vaccine
HA antigens, as measured by ELISA 21 days postvaccination
(Spearman r = 0.8454, p value = 0.002; Figure 1D). Nonsero-
converter 7016 showed a partial response with a 1.58-fold titer
increase for combined TIV antigens and a 2.98-fold increased
clonality index, but there was a strong response to one vaccine
component (5.39-fold change to A/Brisbane/10/2007/H3).
Plasmablast counts in blood after vaccination have been re-
ported to correlate with serological responses (Liao et al.,
2011; Sasaki et al., 2008). Day 7 plasmablast frequencies (Table
S3) in the samples studied here showed significant correlation
with the clonality index (r = 0.8545, p = 0.002, Figure 1D) and a
slightly weaker correlation with changes in serum antibody titer
(r = 0.7182, p = 0.02, Figure 1D). However, the difference be-
tween these two correlations did not meet statistical significance
(p = 0.1214, Steiger’s dependent variable correlation) (Steiger,
1980). Consistent with prior literature, prevaccination titers
were negatively correlated with vaccine-stimulated titer changes
(Figure 1D) (Sasaki et al., 2008).
Clones from IGHDeepSequencingComprise a Subset of
Antigen-Specific Plasmablasts
To directly evaluate the influenza specificity of the detected B
cell expansions and assess whether these represent members
of the plasmablast pool, we compared the data to IGH from
flow-sorted plasmablasts isolated from the same day 7 samples
for five of the seroconverters (7001, 7004, 7014, 7021, and 7024).
A total of 398 sorted plasmablasts were expressed as recombi-
nant monoclonal antibodies (mAbs); their antigen specificities
were evaluated as part of a previous study (Moody et al.,
2011), and 59.8% were influenza reactive.
Analysis revealed that 24.4% of sorted plasmablasts be-
longed to clonally expanded lineages containing IGH identified
by sequencing (Figure 2A; Table S2). Sixty-six percent of the
plasmablast-derived IGHs in these lineages were from influ-
enza HA-binding mAbs (Figure 2B; Table S2). Conversely,
10.2% of the day 7 expanded clones were in lineages that
included plasmablast IGHs. Subject 7001, who contributed
247 mAbs (Moody et al., 2011), shared 19.6% of day 7 clonally
expanded B cell lineages with plasmablast IGHs, and 82.4%
of these included influenza-specific mAbs (Figure 2B;
Table S2). This indicates that at day 7 postvaccination, there
is partial overlap of both the total population of clonally
expanded B cells and plasmablasts sorted on the basis of their
immunophenotype.
Somatic Hypermutation of Vaccine-Stimulated B Cell
Repertoires
Seroconverters and nonseroconverters differed in the somatic
mutation of expanded B cell clones at day 7 postvaccinationc.
Figure 1. Quantitation of Clonal B Cells in the Blood after Vaccination Predicts Seroconversion
(A) Replicate IGH libraries were generated from peripheral-blood B cells for 14 individuals (Table S1) at three time points: prevaccination (red arc), day 7
postvaccination (green arc), and day 21 postvaccination (purple arc). Replicates are shown as bands within each arc, and lines connect clonally related VDJs from
independent replicates. Detailed IGH repertoires for each individual are shown in Movie S1. Figure S1 presents criteria for the definition of clonal lineages.
(B) Normalized clonality index scores; prevaccination (red) and on days 7 (green) and 21 (purple) postvaccination.
(C) Plasmablast percentages of total B cells (Table S3); prevaccination (red) and on days 7 (green) and 21 (purple) postvaccination.
(D) Correlation between metrics and serological antibody response.
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Figure 2. Antigen Specificity of Vaccine-Induced B Cell
Clonal Populations
(A) B cell lineages with members from mAbs derived from day 7
sorted plasmablasts (blue arc) and deep-sequenced IGH from
peripheral B cells prior to (red) and on days 7 (green) and 21 (purple)
after TIV vaccination. Lines join lineage members.
(B) Antigen binding of plasmablast-derived mAbs (Table S2); influ-
enza antigen (green), unknown or untested (yellow), noninfluenza
antigen (red). Arcs are ‘‘zoomed’’ to shared lineages. 7014 had no
shared lineages.
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Clonal Signatures of Influenza Vaccine Responses(mean mutation was 6.4% and 4.3%, respectively, p = 0.0041, t
test). Prior to vaccination, the groups shared similar levels of
mutation in expanded clones (3.2%and 3.4%, p = 1.00) and non-
clonal IGHV sequences (1.5% and 1.3%, p = 0.8048). At day 21,
the expanded lineages of the seroconverters retained a higher
somatic point mutation (5.7%), whereas nonseroconverters
returned to the prevaccination mutation frequency of 3.5% (p =
0.1649).
Time Course of Response to H1N1 Single Antigen
Vaccination
To obtain a more detailed view of the dynamics of the B cell
response to influenza vaccine in a somewhat simpler vaccination
context, we undertook IGH sequencing from a daily time course
of the response to the single-agent pandemic H1N1 2009 influ-
enza vaccination in an additional healthy subject (BFI-278) (Fig-
ure 3A; Movie S2). Prior to vaccination, few clonally expanded B
cell lineages were detected (five expanded clones, on average
0.06% of the total). After vaccination, a clonal response peaked
at day 7 and decreased toward prevaccination levels by day 10
(Figure 3A). Overall, 256 clonal lineages were detected postvac-
cination; 11 lineages were strongly induced by vaccination, and
each contributed more than 0.1% of the total rearrangements.
Vaccine-induced clonal lineages reached their peak at day 7,
when they accounted for 7.1% of total IGH. Many of the vac-
cine-induced expansions continued to be detected by day 9,
although some were observed only at a single time point (Fig-
ure 3A). Clonal lineages utilizing IGHV3-7 paired with IGHJ6
were overrepresented in the vaccine-induced proliferation, and
6 of the 11 prominent lineages used these genes with an 18
amino acid CDR3 (Figure 3B).
The postvaccination clonally expanded IGHs were somatically
mutated, and members of the 11 prominent lineages showed
an average of 5.68% IGHV mutation (Figure 3B). The full IGH
repertoire detected in this individual had a mean IGHV mutation
level of 1.18%.
Identification of Convergent IGH Rearrangements in the
H1N1 Vaccine Response
The dominant IGH lineages in BFI-278’s response to single-
antigen H1N1 vaccination (Figure 3) had stereotyped features:
IGHV3-7, IGHJ6, and an 18 amino acid CDR3. These lineages
were compared to previously reported H1N1-responding B cell
repertoires. Surprisingly, we observed response convergence
with constrained CDR3 sequences seen in two other studies
(Wrammert et al., 2011; Krause et al., 2011). The CDR3 se-
quences of 4K8 and 2K11 (Krause et al., 2011) differed from
member BFI-278’s dominant expansion by a single amino acid
residue (Figures 4A and 4B; Table S4). 48K and 2K11 were iso-
lated from one individual after pandemic H1N1 vaccination,
and both had activity against 2009 H1N1 and human and swine
influenza strains from 1918, 1930, 1976, and 1977 by hemagglu-
tination activation inhibition (HAI) (Krause et al., 2011). Paired
with the light chain of antibody 4K8, a mAb generated from the
IGH isolated from BFI-278 showed HAI with a titer of 20 in tripli-
cate assays against the influenza A H1N1 California/7/09 strain,
but no detectable activity against the other strains in the panel.
Stereotypic IGHs were also present in H1N1-stimulated
clones from a single donor 15 days after acute pandemicCellH1N1 infection (Wrammert et al., 2011). One mAb, 70-1B03,
differed from IGH isolated from BFI-278 by two CDR3 residues
and was reported to be cross-reactive between pandemic
H1N1 and the 2009 annual TIV vaccine antigens (Figure 4C)
(Wrammert et al., 2011). Two further IGHs, 70-5E04H and 70-
1F05H, were derived from H1N1-infection-induced plasma-
blasts but had no detectable binding to the panel of antigens
tested (Wrammert et al., 2011).
We examined somatic mutations in IGHV to assess additional
evidence of molecular convergence in these antibodies. Overall,
the IGHV of convergent H1N1-specific lineage members from
BFI-278 showed an average of 5.24% mutation, and the most
highly mutated sequence showed 12.27%mutation. Somatically
mutated positions in CDR1 and CDR2 were shared with 4K8 and
2K11 mAbs (Figure 4D). Shared substitutions could result from
intrinsic mutation hotspots favoring mutation at these locations.
This is very unlikely for the observed convergent mutations, as
the CDR1 and CDR2 mutations in the BFI-278 H1N1 antibody
sequences were uncommon in two unrelated, nonvaccinated
data sets: IGHV3-7 IGH from the prevaccination of 14 TIV 2007
and 2008 subjects (Figure 4D) and IGHV3-7 IGH from 27 healthy
subjects who had not been recently vaccinated (Wang et al.,
2014) (both p < 0.0001, Pearson’s dependent groups). Impor-
tantly, the two nonvaccination data sets were highly similar in
their mutations (r = 0.9311), and both were distinct from the
H1N1 lineages (p = 0.1794). Evaluation of mutated positions in
mAbs 48K and 2K11 for whether they were more likely to have
been drawn from the mutation distribution of the H1N1 lineage
or from the two nonvaccination data sets showed that 4K8 car-
riedmutations similar to those of theH1N1 lineage (log-likelihood
ratio =7.98 for H1N1 and22.59 for the IGHV3-7 background),
whereas 2K11 did not show higher similarity to either distribution
(41.97 for H1N1 and 42.52 for the IGHV3-7 background).
The response of BFI-278 to the next year’s 2010 TIV, which
included pandemic H1N1, was also examined. The 2010 TIV
response included 28 IGHs with stereotypic features at day 7
postvaccination (0.36%). These differed from the prior year’s
stereotypic clones by at least four CDR3 residues, from the
H1N1-stimulated B cells from Wrammert et al. (2011) by more
than five positions, and from the H1N1-specific mAbs from
Krause et al. (2011) by six positions. The 2010 TIV IGH also
lacked convergent somatic mutations and therefore appeared
to represent distinct B cell clones.
IGH Rearrangements with Stereotypic Features Prior to
2009
To evaluate whether the convergent B cell clones were present
at high frequencies in BFI-278’s repertoire prior to pandemic
H1N1 antigen exposure, we studied previously reported sam-
ples collected 14 months apart in 2006 and 2008 (Boyd et al.,
2009). Only four IGHs from 2006 (0.03%) and ten IGHs from
2008 (0.06%) used IGHV3-7 and IGHJ6 with an 18 amino acid
CDR3. The CDR3s of the pre-2009 IGHs differed from the
H1N1 response clones by at least six amino acids and appeared
to be unrelated.
The contribution of stereotypic IGH chains in independent
populations was also analyzed in 151,217 unique IGHs pooled
from IGH sequencing of 27 additional adults (2008 and 2009)
(Wang et al., 2014). IGH using IGHV3-7 and IGHJ6 representedHost & Microbe 16, 105–114, July 9, 2014 ª2014 Elsevier Inc. 109
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Figure 3. TimeCourse of BCell Clonal Expansions
Induced by Inactivated H1N1 Vaccine
(A) Vaccine-induced B cell clonal lineage relationships
during H1N1 vaccine response (complete IGH repertoires
are shown in Movie S2). Each arc represents a post-
vaccination time point subdivided into expanded (blue)
and unexpanded (yellow) compartments. Lines join line-
age members at later time points. Orange lines indicate
that a lineage was strongly induced at the originating time
point (>0.1% of total IGH).
(B) IGHV mutation percentage for strongly induced line-
ages. Median (red line), quartiles shown as box and
whiskers, and points are jittered for preventing over-
plotting.
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Clonal Signatures of Influenza Vaccine Responses1.01% of total rearrangements, and 115 of these IGHs had an 18
amino acid CDR3. The 115 rearrangements did not share similar
CDR3 sequences with IGH from BFI-278’s H1N1 vaccination; all
had less than 85% sequence identity. Among 496,104 IGH
sequences from the 14 TIV 2007 and 2008 subjects, a single
IGH (seroconverter 7014, 2008 TIV) differed from a rearrange-
ment from individual BFI-278’s H1N1 2009 response by one
amino acid residue. Examination of over 500,000 IGH sequences
collected from 41 individuals prior to 2009 therefore revealed
only a single example of the convergent IGH seen in 2009 in
BFI-278 and in the Wrammert et al. (2011) and Krause et al.
(2011) studies, indicating that antibody lineages capable of
binding the pandemic H1N1 strain were indeed present in human
B cell repertoires but were relatively rare.
DISCUSSION
Deep sequencing of immunoglobulin libraries enables tracking of
known antigen-specific B cell populations (Liao et al., 2011; Liao
et al., 2009; Wu et al., 2011). In addition, replicate libraries of B
cells from an individual can identify clonally expanded popula-
tions arising in response to immune stimuli, such as vaccination
or infection. Recently, influenza vaccine responses in humans
have been associated with increased numbers of plasmablast
immunophenotype B cells in the blood; these B cells peak at
approximately 7 days postexposure, and the majority express
antibodies specific to influenza antigens and often feature signif-
icant clonal expansion of particular plasmablast lineages (Brok-
stad et al., 1995; Cox et al., 1994; Halliley et al., 2010; Sasaki
et al., 2007; Wrammert et al., 2008). Prior deep-sequencing
analysis of responses to influenza vaccination has identified
sequences present at elevated levels in libraries amplified from
cDNA of peripheral-blood B cells (Jiang et al., 2013). Our results
reveal a strong correlation between the levels of B cell clonal
expansion detected in the blood and the serological response
to vaccination. Vaccine-induced clonal lineages measured by
replicate library sequencing peaked at day 7 after having
increased 118-fold over background lineages and persisted at
detectable levels until about 2 weeks postvaccination.
To evaluate the antigen specificity of the clones detected by
sequencing, we compared our data to the sequences of mAbs
generated from plasmablasts at day 7 postvaccination individ-
uals who seroconverted to seasonal TIV (Moody et al., 2011).
Almost 25% of the IGH utilized by the plasmablast-derived
mAbs shared clonal lineages with those we identified, and
66% of these were specific to influenza. This cross-identification
confirms that a relatively simple evaluation of clonal expansions
in the vaccine response by IGH repertoire sequencing highlights
antigen-specific lineages. In addition, the incomplete overlap
suggests that there are low-frequency plasmablast lineages
that are not identified as clonally expanded and that there may
be other clonally expanded B cell populations that do not have
a plasmablast immunophenotype, such as influenza-specific
memory B cells, which have been previously reported to signifi-
cantly increase their levels in the blood at day 7 after influenza
vaccination (Wrammert et al., 2008).
Unexpectedly, the response to monovalent H1N1 vaccination
showed striking stereotypic features (use of IGHV3-7, IGHJ6,
and an 18 amino acid CDR3) in themost prominent postvaccina-Celltion clonally expanded B cell lineages. We looked for evidence of
this stereotypic IGH response in other individuals responding to
influenza vaccination or infection and expected that the likeli-
hood of finding ‘‘convergent evolution’’ in antibody responses
to influenza would be low, given that the immunoglobulin reper-
toire is potentially very large, that deep sequencing still permits
relatively shallow sampling of each individual’s repertoire
(Boyd et al., 2009; Glanville et al., 2011), and that selection pres-
sures on influenza strains avoid common immune responses. To
our surprise, IGH from two independent H1N1 response studies
(Krause et al., 2011; Wrammert et al., 2011) shared the stereo-
typic features. The CDR3s of these rearrangements differed by
only 1 or 2 of 18 amino acids, highlighting a striking degree of
convergence in the antibody responses in these unrelated indi-
viduals. Paired with the light chain from the previously reported
48K mAb (Wrammert et al., 2011), a recombinant mAb of the
BFI-278 stereotypic IGH lineage showed HAI specific to the
pandemic H1N1 strain. Notably, in a search of over 500,000
IGH sequences from the B cell repertoires of 41 subjects studied
from 2006 to 2009, we identified a single IGH with the same
convergent features, highlighting the low prior frequency of
such clones that are preferentially stimulated by the 2009
pandemic H1N1 influenza strain (Brokstad et al., 1995; Sasaki
et al., 2007).
The use of IGH involving IGHV3-7, IGHJ6, and an 18
amino acid CDR3 was a recurrent pattern of the response of
BFI-278 (Figure 3) to successive years of H1N1 influenza
vaccination, but importantly, the stereotyped B cell clones in
2009 were distinct from those that appeared in 2010 after
vaccination with TIV containing the same pandemic H1N1
antigens. This suggests the recruitment of new B cells with
stereotypic IGH chains rather than a recall response dominated
by the highest-frequency members of the prior year’s clones.
This favoring of new clones could be due to the fact that serum
antibody derived from the 2009 vaccination decreases restimu-
lation of the dominant 2009 B cell clones but doesn’t prevent
stimulation of B cells that recognize somewhat different epitopes
of the viral antigens.
In summary, high-throughput DNA sequencing of peripheral-
blood B cells provides a highly informative measure of clonal
expansions, and such a measure correlates with serological
vaccine responses. B cell clones that expand after vaccination
show substantial but incomplete clonal overlap with vaccine-
specific single-cell plasmablasts. Responses to vaccination
with the 2009 pandemic H1N1 influenza strain revealed a domi-
nant pattern of antibody responsiveness that was convergent in
different individuals. Antibodies with convergent features were
rare prior to 2009. Overall, if the detection of convergent anti-
body signatures can be generalized to other antigens and in-
fectious diseases, it may be feasible to use IGH repertoire
sequencing to assess an individual’s history of antigenic expo-
sures and infections more broadly (Glanville et al., data not
shown). The results also lend some support to the idea that
evolutionary selection of the germline IGH genes may predis-
pose the adaptive immune response to follow common paths
of response to common pathogens. Further evaluation in the
context of different vaccines and pathogen infections will be
able to determine whether these findings are the exception or
the rule in human antibody responses.Host & Microbe 16, 105–114, July 9, 2014 ª2014 Elsevier Inc. 111
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A
B
C
D
CDR1 CDR2
*
*
*
*
CSG1 1 1
CSG3
CSG2
2
2
2
2
2
2
2
2
2
2
11
1
4
4
2
8
2
1
51
12
ID HDa nb
4K8
IGHV3-7*01
IGHD6-13*01
IGHD5-5/18*01
IGHJ6*02
70-1B03H
70-1F05H
70-5E04H
CSG4 1 7
2
2
2
2
2
2
48
39
3
2
1
1
CSG5
IGHV3-7*01
IGHD5-5/18*01
IGHJ6*02
IGHD4-17*01
CSG7
CSG6 2
2 5
1
IGHV3-7*01
IGHD5-5/18*01
IGHJ6*02
a HD: hamming distance between the CDR3s of the common sequence group (CSG) members and the mAb
b
 n: number of members of CSG from deep sequencing
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Collection of Specimens
All subject recruitment was performed with informed consent. The Duke
University institutional review board (IRB) approved protocols for the study
of response to 2007 and 2008 seasonal TIV. The Stanford University IRB
approved the study of the 27 additional prevaccination subjects. Subjects re-
cruited at Duke University were given either 2007–2008 or 2008–2009 FluZone
TIV (Sanofi Pasteur) as described in Table S1 and detailed in the Supplemental
Information. Blood was drawn before vaccination and on days 7 and 21 after
challenge. Subjects recruited at Stanford University were 27 healthy individ-
uals aged 20–89 years (Wang et al., 2014). Peripheral-blood samples from
these patients were collected prior to vaccination in two successive years
(2008 and 2009).
Subject BFI-278, recruited at Stanford University, was administered the
2009 monovalent inactivated vaccination to influenza A (H1N1) in January
2010. Blood was drawn before vaccination and daily on days 4–14 after chal-
lenge. Ten months after receiving the monovalent H1N1 vaccine, BFI-278 was
administered a seasonal TIV that included the influenza A/California/07/2009-
like pandemic H1N1 antigenic component. Blood was drawn prior to 2010 TIV
vaccination and on days 7 and 21 postvaccination.
Sample Preparation and PCR Amplification for Deep Sequencing
Peripheral-blood mononuclear cells (PBMCs) were isolated by centrifugation
of blood layered over Histopaque-1077 (Sigma-Aldrich) and cryopreserved
(Moody et al., 2011). Column purification (QIAGEN) was used for isolating
genomic DNA template. IGHs were amplified from genomic DNA template
with the previously described primer design for 454 instrument sequencing
as detailed in the Supplemental Information (Boyd et al., 2009).
Deep Sequencing of IGH
Amplicon library pools were quantified by real-time PCR (Roche). Sequencing
data presented here were derived from the 454 instrument with the use of
Titanium chemistry; long-range amplicon pyrosequencing began from the
‘‘B’’ primer in the manufacturer’s protocol (Roche). The complete data sets
from the samples generated are available at dbGaP accession number
phs000760.v1.p1.
Analysis of Sequence Data
Sequences from each input specimen were demultiplexed with the sample
and replicate library barcodes as detailed in the Supplemental Information.
Alignment of rearranged IGH sequences to germline V, D, and J and determi-
nation of V-D junctions and D-J junctions were performed with iHMMune-align
(Gae¨ta et al., 2007). IGHs were assigned to clonal lineages by means of
clustering on CDR3 nucleotide similarity for IGHs that shared the same
IGHV, IGHJ, and CDR3 length. CDR3 sequence similarity was measured by
Hamming distance, and clusters were assigned with a Hamming distance of
95% identity to any existing sequence and at least 80% identity within the
cluster (Figure S1).
Scale-Independent Normalized Measure of Overall Clonality
To compare the degree of B cell clonal expansion detected in data sets with
varying sequencing depth, we used a scale-independent metric we have pre-
viously described (Wang et al., 2014). This clonality metric can be consideredFigure 4. Convergent IGH Rearrangements Identified in H1N1 Vaccine
Multiple-sequence alignment of closely related stereotypic H1N1 clones isolated
the germline genes (top of each block). Nucleotides inferred to be derived from n
Amino acid positions are labeled when they differ from those in the mAb (bottom o
group (CSG), and the mAb. Members of CSGs are detailed in Table S4.
(A) IGH related to mAb 4K8 (Krause et al., 2011).
(B) IGH related to mAb 2K11 (Krause et al., 2011).
(C) IGH related to CDR3s previously identified by Wrammert et al. (2011).
(D) The percentage of total sequences with CDR1 and CDR2 somatic amino acid
using IGHV3-7 from the prevaccination repertoire of 14 subjects prepandemic (lo
mark amino acid substitutions shared with mAbs 48K or 2K11 (Krause et al., 201
Cellthe probability that any two randomly selected sequences drawn from inde-
pendent replicates are members of the same clonal lineage.
Analysis of Hypermutation Spectra
CDR1 and CDR2 sequences, as defined by IMGT criteria, were extracted from
iHMMune-align results and translated to amino acid sequences. CDR1 and
CDR2 position count matrices of mutations were converted to substitution
frequency vectors. Pearson’s correlation and Pearson’s test for dependent
correlations were used for assessing whether there were differences between
mutation spectra for different data sets. Log-likelihood ratios were used for
exploring single-sequence mutation distributions, allowing comparison of
the likelihood that the observed substitutions were drawn from the mutation
distributions of different data sets.
Single-Cell Plasmablast Sorting, mAb Expression, and
Quantification of Plasmablast Frequencies
PBMCs were cryopreserved with standard methods, and single-cell sorting
was performed as previously described (Moody et al., 2011). Flow cytometry
was carried out prior to single-cell IGH V(D)J PCR and expression of recombi-
nant IgG1 mAbs as previously described (Liao et al., 2009; Moody et al., 2011)
and detailed in the Supplemental Information. In addition, samples collected
prior to vaccination and days 7 and 21 postvaccination were assessed for
plasmablast and B cell phenotypes.
Serum Antibody Binding Tests
Plasma samples were evaluated by ELISA with purified HAs and split vaccine
preparations as detailed in the Supplemental Information. Five-parameter
curve fits were used for data analysis. Endpoint titers were calculated as
3-fold above assay background, and the assay cutoff was a 1:25 dilution.
Expressed mAbs were tested for binding to influenza antigen by ELISA, as
previously described (Moody et al., 2011). Reactivity to influenza antigens
was also studied with a standardized custom Luminex assay.
HAI of mAbs
HAI assays of mAbs were performed as described elsewhere (Davtyan et al.,
2011; Wang et al., 2006) and are detailed in the Supplemental Information.
Working stocks of influenza were standardized to a HA titer of 8 HA units
per 50 ml for assays for A/California/4/2009 (H1N1), A/Brisbane/59/2007
(H1N1), A/Brisbane/10/2007 (H3N2), B/Brisbane/60/2008, and B/Florida/4/
2006. The HAI titer was defined as the reciprocal of the highest dilution of anti-
body that inhibits red blood cell hemagglutination by influenza virus.ACCESSION NUMBERS
The dbGaP accession number for themetadata and sequences reported in the
paper is phs000760.v1.p1.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure, four tables, Supplemental
Experimental Procedures, and two movies and can be found with this article
online at http://dx.doi.org/10.1016/j.chom.2014.05.013.Responses in Different Individuals
from difference sources. Nucleotide positions are labeled when they differ from
ontemplated nucleotide addition during V(D)J rearrangement are not colored.
f each block). Each block is labeled with the germline, the conserved sequence
substitutions in convergent H1N1 clones (upper) in comparison to 4,784 IGHs
wer). The germline sequence is depicted in the white boxes (middle). Asterisks
1).
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